Eli Lilly is surging past SpaceX in market value, riding a wave of profitable GLP-1 dominance while the rocket company remains unprofitable and vulnerable to earnings shocks and insider selling. With Lilly up 25% in six months and revenue soaring 48%, analysts see its valuation as justified — though SpaceX’s $1.8T valuation still dwarfs Lilly’s $1.1T. While Lilly won’t catch SpaceX by year-end, it could overtake it long-term — if SpaceX’s stock doesn’t face major setbacks soon. For now, Lilly looks like the safer, smarter bet.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
